Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy
Cancer-related anaemia is associated with a wide spectrum of symptoms that can negatively affect quality of life. Because epoetin alfa has demonstrated efficacy in correcting cancer-related anaemia, the impact of this treatment on quality of life was evaluated in a multinational, randomised, double-...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 2002-12, Vol.87 (12), p.1341-1353 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1353 |
|---|---|
| container_issue | 12 |
| container_start_page | 1341 |
| container_title | British journal of cancer |
| container_volume | 87 |
| creator | Fallowfield, L Gagnon, D Zagari, M Cella, D Bresnahan, B Littlewood, T J McNulty, P Gorzegno, G Freund, M |
| description | Cancer-related anaemia is associated with a wide spectrum of symptoms that can negatively affect quality of life. Because epoetin alfa has demonstrated efficacy in correcting cancer-related anaemia, the impact of this treatment on quality of life was evaluated in a multinational, randomised, double-blind, placebo-controlled trial in 375 anaemic cancer patients receiving non-platinum-based chemotherapy. The cancer-specific measures of quality of life included the general scale (FACT-G Total) and fatigue subscale (FACT-An Fatigue subscale) of the Functional Assessment of Cancer Therapy-Anaemia and the Cancer Linear Analogue Scales measuring energy, ability to do daily activities, and overall quality of life. These measures were also used to examine the relationship between haemoglobin levels and quality of life. Both univariate and multiple linear regression analyses of quality of life data were performed. Results of the univariate analysis have been reported previously. The
a priori-
planned multiple linear regression analysis, which accounted for the effects of disease progression and several other possibly confounding variables on quality of life, showed a significant advantage for epoetin alfa over placebo for the five scales (all,
P |
| doi_str_mv | 10.1038/sj.bjc.6600657 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2376290</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72722235</sourcerecordid><originalsourceid>FETCH-LOGICAL-c505t-d4f092bd862231a742b5728a3d2a4c65afdf63673c249a03406b0207888a04a93</originalsourceid><addsrcrecordid>eNp1kk2P0zAQhiMEYpeFKzeQhQQn0nUcJ04uSGjFl7SIC5ytiT1pXTl21nYq9e_xy3DVsgUkTtZ4nnnn1cwUxfOKripad9dxuxq2atW2lLaNeFBcVk3Nyqpj4mFxSSkVJe0ZvSiexLjNYU878bi4qBhvuGjpZfHz62KT2UEwkJAEXAeM0XhHwIHdR4zEj0RDAjIGPxEgAZz2k4mo3xLtl8FiOVjjcjRbUDj4UnmXgrcWNYlp0XuSP0YTJnK3gDVpf1C0ZkQyoMPRpEOMs8dkclc7AsnvDMmgSzE7Umh2xq2J867MLTK1TERtcPJpgwHm_dPi0Qg24rPTe1X8-Pjh-83n8vbbpy83729L1dAmlZqPeRSD7lrG6goEZ0MjWAe1ZsBV28Cox7ZuRa0Y74HWnLYDZVR0XQeUQ19fFe-OuvMyTKhV9hfAyjmYCcJeejDy74wzG7n2O8lq0bKeZoE3J4Hg7xaMSeY5KrQWHPolSsEEy96aDL76B9z6JeSFRMkYrTjl_cHO6gip4GMMON47qag83IaMW5lvQ55uIxe8_NP_GT8dQwZenwCIKm8ir1qZeOZ43XPOeOauj1zMKbfGcLb339YvjhUO0hLwXvJ3_hdGBOGB</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>220140499</pqid></control><display><type>article</type><title>Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy</title><source>MEDLINE</source><source>Nature</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Fallowfield, L ; Gagnon, D ; Zagari, M ; Cella, D ; Bresnahan, B ; Littlewood, T J ; McNulty, P ; Gorzegno, G ; Freund, M</creator><creatorcontrib>Fallowfield, L ; Gagnon, D ; Zagari, M ; Cella, D ; Bresnahan, B ; Littlewood, T J ; McNulty, P ; Gorzegno, G ; Freund, M ; Epoetin Alfa Study Group ; for the Epoetin Alfa Study Group</creatorcontrib><description>Cancer-related anaemia is associated with a wide spectrum of symptoms that can negatively affect quality of life. Because epoetin alfa has demonstrated efficacy in correcting cancer-related anaemia, the impact of this treatment on quality of life was evaluated in a multinational, randomised, double-blind, placebo-controlled trial in 375 anaemic cancer patients receiving non-platinum-based chemotherapy. The cancer-specific measures of quality of life included the general scale (FACT-G Total) and fatigue subscale (FACT-An Fatigue subscale) of the Functional Assessment of Cancer Therapy-Anaemia and the Cancer Linear Analogue Scales measuring energy, ability to do daily activities, and overall quality of life. These measures were also used to examine the relationship between haemoglobin levels and quality of life. Both univariate and multiple linear regression analyses of quality of life data were performed. Results of the univariate analysis have been reported previously. The
a priori-
planned multiple linear regression analysis, which accounted for the effects of disease progression and several other possibly confounding variables on quality of life, showed a significant advantage for epoetin alfa over placebo for the five scales (all,
P
<0.05), and confirmed the results of the univariate analysis. For cancer-specific measures, significant correlations were demonstrated between baseline haemoglobin and quality of life (
r
, range: 0.14–0.26, all
P
<0.05) and between change in haemoglobin and change in quality of life (
r
, range: 0.26–0.34, all
P
<0.01). These findings provide evidence that increasing haemoglobin levels by epoetin alfa administration can significantly improve cancer patients' quality of life.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/sj.bjc.6600657</identifier><identifier>PMID: 12454760</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Activities of Daily Living ; Adolescent ; Adult ; Aged ; Aged, 80 and over ; Anemia - chemically induced ; Anemia - drug therapy ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Biomedicine ; Cancer Research ; Clinical ; Double-Blind Method ; Drug Resistance ; Drug toxicity and drugs side effects treatment ; Epidemiology ; Epoetin Alfa ; Erythropoietin - therapeutic use ; Female ; Hematinics - therapeutic use ; Hemoglobins - analysis ; Humans ; Male ; Medical sciences ; Middle Aged ; Molecular Medicine ; Neoplasms - drug therapy ; Neoplasms - mortality ; Oncology ; Pharmacology. Drug treatments ; Quality of Life ; Recombinant Proteins ; Survival Rate ; Toxicity: blood ; Treatment Outcome</subject><ispartof>British journal of cancer, 2002-12, Vol.87 (12), p.1341-1353</ispartof><rights>The Author(s) 2002</rights><rights>2003 INIST-CNRS</rights><rights>Copyright 2002 Cancer Research UK</rights><rights>Copyright Nature Publishing Group Dec 2, 2002</rights><rights>Copyright © 2002 Cancer Research UK 2002 Cancer Research UK</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c505t-d4f092bd862231a742b5728a3d2a4c65afdf63673c249a03406b0207888a04a93</citedby><cites>FETCH-LOGICAL-c505t-d4f092bd862231a742b5728a3d2a4c65afdf63673c249a03406b0207888a04a93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376290/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376290/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,2727,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14394424$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12454760$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fallowfield, L</creatorcontrib><creatorcontrib>Gagnon, D</creatorcontrib><creatorcontrib>Zagari, M</creatorcontrib><creatorcontrib>Cella, D</creatorcontrib><creatorcontrib>Bresnahan, B</creatorcontrib><creatorcontrib>Littlewood, T J</creatorcontrib><creatorcontrib>McNulty, P</creatorcontrib><creatorcontrib>Gorzegno, G</creatorcontrib><creatorcontrib>Freund, M</creatorcontrib><creatorcontrib>Epoetin Alfa Study Group</creatorcontrib><creatorcontrib>for the Epoetin Alfa Study Group</creatorcontrib><title>Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>Cancer-related anaemia is associated with a wide spectrum of symptoms that can negatively affect quality of life. Because epoetin alfa has demonstrated efficacy in correcting cancer-related anaemia, the impact of this treatment on quality of life was evaluated in a multinational, randomised, double-blind, placebo-controlled trial in 375 anaemic cancer patients receiving non-platinum-based chemotherapy. The cancer-specific measures of quality of life included the general scale (FACT-G Total) and fatigue subscale (FACT-An Fatigue subscale) of the Functional Assessment of Cancer Therapy-Anaemia and the Cancer Linear Analogue Scales measuring energy, ability to do daily activities, and overall quality of life. These measures were also used to examine the relationship between haemoglobin levels and quality of life. Both univariate and multiple linear regression analyses of quality of life data were performed. Results of the univariate analysis have been reported previously. The
a priori-
planned multiple linear regression analysis, which accounted for the effects of disease progression and several other possibly confounding variables on quality of life, showed a significant advantage for epoetin alfa over placebo for the five scales (all,
P
<0.05), and confirmed the results of the univariate analysis. For cancer-specific measures, significant correlations were demonstrated between baseline haemoglobin and quality of life (
r
, range: 0.14–0.26, all
P
<0.05) and between change in haemoglobin and change in quality of life (
r
, range: 0.26–0.34, all
P
<0.01). These findings provide evidence that increasing haemoglobin levels by epoetin alfa administration can significantly improve cancer patients' quality of life.</description><subject>Activities of Daily Living</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anemia - chemically induced</subject><subject>Anemia - drug therapy</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Clinical</subject><subject>Double-Blind Method</subject><subject>Drug Resistance</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Epidemiology</subject><subject>Epoetin Alfa</subject><subject>Erythropoietin - therapeutic use</subject><subject>Female</subject><subject>Hematinics - therapeutic use</subject><subject>Hemoglobins - analysis</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Molecular Medicine</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - mortality</subject><subject>Oncology</subject><subject>Pharmacology. Drug treatments</subject><subject>Quality of Life</subject><subject>Recombinant Proteins</subject><subject>Survival Rate</subject><subject>Toxicity: blood</subject><subject>Treatment Outcome</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kk2P0zAQhiMEYpeFKzeQhQQn0nUcJ04uSGjFl7SIC5ytiT1pXTl21nYq9e_xy3DVsgUkTtZ4nnnn1cwUxfOKripad9dxuxq2atW2lLaNeFBcVk3Nyqpj4mFxSSkVJe0ZvSiexLjNYU878bi4qBhvuGjpZfHz62KT2UEwkJAEXAeM0XhHwIHdR4zEj0RDAjIGPxEgAZz2k4mo3xLtl8FiOVjjcjRbUDj4UnmXgrcWNYlp0XuSP0YTJnK3gDVpf1C0ZkQyoMPRpEOMs8dkclc7AsnvDMmgSzE7Umh2xq2J867MLTK1TERtcPJpgwHm_dPi0Qg24rPTe1X8-Pjh-83n8vbbpy83729L1dAmlZqPeRSD7lrG6goEZ0MjWAe1ZsBV28Cox7ZuRa0Y74HWnLYDZVR0XQeUQ19fFe-OuvMyTKhV9hfAyjmYCcJeejDy74wzG7n2O8lq0bKeZoE3J4Hg7xaMSeY5KrQWHPolSsEEy96aDL76B9z6JeSFRMkYrTjl_cHO6gip4GMMON47qag83IaMW5lvQ55uIxe8_NP_GT8dQwZenwCIKm8ir1qZeOZ43XPOeOauj1zMKbfGcLb339YvjhUO0hLwXvJ3_hdGBOGB</recordid><startdate>20021202</startdate><enddate>20021202</enddate><creator>Fallowfield, L</creator><creator>Gagnon, D</creator><creator>Zagari, M</creator><creator>Cella, D</creator><creator>Bresnahan, B</creator><creator>Littlewood, T J</creator><creator>McNulty, P</creator><creator>Gorzegno, G</creator><creator>Freund, M</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20021202</creationdate><title>Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy</title><author>Fallowfield, L ; Gagnon, D ; Zagari, M ; Cella, D ; Bresnahan, B ; Littlewood, T J ; McNulty, P ; Gorzegno, G ; Freund, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c505t-d4f092bd862231a742b5728a3d2a4c65afdf63673c249a03406b0207888a04a93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Activities of Daily Living</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anemia - chemically induced</topic><topic>Anemia - drug therapy</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Clinical</topic><topic>Double-Blind Method</topic><topic>Drug Resistance</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Epidemiology</topic><topic>Epoetin Alfa</topic><topic>Erythropoietin - therapeutic use</topic><topic>Female</topic><topic>Hematinics - therapeutic use</topic><topic>Hemoglobins - analysis</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Molecular Medicine</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - mortality</topic><topic>Oncology</topic><topic>Pharmacology. Drug treatments</topic><topic>Quality of Life</topic><topic>Recombinant Proteins</topic><topic>Survival Rate</topic><topic>Toxicity: blood</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fallowfield, L</creatorcontrib><creatorcontrib>Gagnon, D</creatorcontrib><creatorcontrib>Zagari, M</creatorcontrib><creatorcontrib>Cella, D</creatorcontrib><creatorcontrib>Bresnahan, B</creatorcontrib><creatorcontrib>Littlewood, T J</creatorcontrib><creatorcontrib>McNulty, P</creatorcontrib><creatorcontrib>Gorzegno, G</creatorcontrib><creatorcontrib>Freund, M</creatorcontrib><creatorcontrib>Epoetin Alfa Study Group</creatorcontrib><creatorcontrib>for the Epoetin Alfa Study Group</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fallowfield, L</au><au>Gagnon, D</au><au>Zagari, M</au><au>Cella, D</au><au>Bresnahan, B</au><au>Littlewood, T J</au><au>McNulty, P</au><au>Gorzegno, G</au><au>Freund, M</au><aucorp>Epoetin Alfa Study Group</aucorp><aucorp>for the Epoetin Alfa Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2002-12-02</date><risdate>2002</risdate><volume>87</volume><issue>12</issue><spage>1341</spage><epage>1353</epage><pages>1341-1353</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>Cancer-related anaemia is associated with a wide spectrum of symptoms that can negatively affect quality of life. Because epoetin alfa has demonstrated efficacy in correcting cancer-related anaemia, the impact of this treatment on quality of life was evaluated in a multinational, randomised, double-blind, placebo-controlled trial in 375 anaemic cancer patients receiving non-platinum-based chemotherapy. The cancer-specific measures of quality of life included the general scale (FACT-G Total) and fatigue subscale (FACT-An Fatigue subscale) of the Functional Assessment of Cancer Therapy-Anaemia and the Cancer Linear Analogue Scales measuring energy, ability to do daily activities, and overall quality of life. These measures were also used to examine the relationship between haemoglobin levels and quality of life. Both univariate and multiple linear regression analyses of quality of life data were performed. Results of the univariate analysis have been reported previously. The
a priori-
planned multiple linear regression analysis, which accounted for the effects of disease progression and several other possibly confounding variables on quality of life, showed a significant advantage for epoetin alfa over placebo for the five scales (all,
P
<0.05), and confirmed the results of the univariate analysis. For cancer-specific measures, significant correlations were demonstrated between baseline haemoglobin and quality of life (
r
, range: 0.14–0.26, all
P
<0.05) and between change in haemoglobin and change in quality of life (
r
, range: 0.26–0.34, all
P
<0.01). These findings provide evidence that increasing haemoglobin levels by epoetin alfa administration can significantly improve cancer patients' quality of life.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>12454760</pmid><doi>10.1038/sj.bjc.6600657</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 2002-12, Vol.87 (12), p.1341-1353 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2376290 |
| source | MEDLINE; Nature; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Activities of Daily Living Adolescent Adult Aged Aged, 80 and over Anemia - chemically induced Anemia - drug therapy Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Biological and medical sciences Biomedicine Cancer Research Clinical Double-Blind Method Drug Resistance Drug toxicity and drugs side effects treatment Epidemiology Epoetin Alfa Erythropoietin - therapeutic use Female Hematinics - therapeutic use Hemoglobins - analysis Humans Male Medical sciences Middle Aged Molecular Medicine Neoplasms - drug therapy Neoplasms - mortality Oncology Pharmacology. Drug treatments Quality of Life Recombinant Proteins Survival Rate Toxicity: blood Treatment Outcome |
| title | Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T23%3A51%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Multivariate%20regression%20analyses%20of%20data%20from%20a%20randomised,%20double-blind,%20placebo-controlled%20study%20confirm%20quality%20of%20life%20benefit%20of%20epoetin%20alfa%20in%20patients%20receiving%20non-platinum%20chemotherapy&rft.jtitle=British%20journal%20of%20cancer&rft.au=Fallowfield,%20L&rft.aucorp=Epoetin%20Alfa%20Study%20Group&rft.date=2002-12-02&rft.volume=87&rft.issue=12&rft.spage=1341&rft.epage=1353&rft.pages=1341-1353&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/sj.bjc.6600657&rft_dat=%3Cproquest_pubme%3E72722235%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=220140499&rft_id=info:pmid/12454760&rfr_iscdi=true |